Glioblastoma (GBM) is the most common primary brain tumor with median survival of approximately one year. This dismal poor prognosis is due to resistance to currently available chemotherapeutics; therefore, new cytotoxic agents are urgently needed. In the present study, we reported the cytotoxicity of toosendanin (TSN) in the GBM U87 and C6 cell lines in vitro and in vivo. By using the MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide) assay, flow cytometry analysis, and Western blot, we found that TSN inhibited U87 and C6 cell proliferation and induced apoptosis at a concentration as low as 10 nM. Administration of TSN also reduced tumor burden in a xenograft model of athymic nude mice. Pharmacological and molecular studies suggested that estrogen receptor β (ERβ) and p53 were prominent targets for TSN. GBM cell apoptosis induced by TSN was a stepwise biological event involving the upregulation of ERβ and contextual activation of functional p53. Collectively, our study indicates, for the first time, that TSN is a candidate of novel anti-cancer drugs for GBM. Furthermore, ERβ and p53 could act as predictive biomarkers for the sensitivity of cancer to TSN.
10 March 2025 in International Journal of Medical Sciences
Background: Type 2 diabetes (T2D) is a global metabolic condition associated with complications of multiple organs, including the bone. However, the exact impact of T2D on bone along the disease progression, particularly in the early phase, remains largely unknown.
Wound healing involves a complex cascade of regenerative processes, particularly angiogenesis and immunomodulation, the orchestration of which is highly important for efficient repair of tissue defects. However, there is currently a lack of feasible strategies to coordinate angiogenesis and immunomodulation during cutaneous wound management, leading to non-healed skin defects a persistent clinical challenge. In this study, by harnessing the natural immunomodulatory property of splenic matrix and the intrinsic angiogenic effects of apoptotic vesicles (ApoVs), we developed a composite system loading ApoVs derived from stem cells of human exfoliated deciduous teeth (SHED-ApoVs) onto a porcine decellularized splenic matrix-based hydrogel (pDSMG). This pDSMG/SHED-ApoVs system maintains sustainable release of functionalized ApoVs to boost angiogenesis in the early phase of wound healing. Furthermore, the system also preserves the pDSMG capacity of immunomodulation, such as promoting M2 macrophage polarization, Treg differentiation and anti-inflammatory cytokines. With these synergistic effects, pDSMG/SHED-ApoVs creates an optimal regenerative microenvironment and significantly accelerates cutaneous wound healing, which is mechanistically mediated through inhibiting the glycolytic metabolism. Collectively, an innovative bioactive material system of pDSMG/SHED-ApoVs has been established, which safeguards efficient wound healing through concerted actions on angiogenesis and immunomodulation. With translational advantages of pDSMG/SHED-ApoVs, this approach holds potential for clinical wound management.
Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have emerged as a promising cell-free therapeutic strategy in regenerative medicine and immunomodulation. These nanosized vesicles, carrying bioactive molecules like miRNAs, proteins, and lipids, exhibit dual capabilities in regulating immune responses and promoting tissue repair. MSC-EVs promote tissue regeneration, including revascularization, skeletal and dental tissue repair, wound healing, hepatic and renal regeneration, and neural repair. Simultaneously, their immunomodulatory properties-suppressing excessive inflammation and regulating immune cell activity, make them promising interventions for autoimmune, neurodegenerative, and inflammatory conditions. By integrating tissue repair with immune regulation, MSC-EVs represent a transformative paradigm in precision therapeutics, meriting accelerated clinical exploration.